Answers are grounded in this paper and cite their sources.
We examined the stimulatory effects of lubiprostone, a bicyclic fatty acid derived from prostaglandin E 1 and a chloride channel type-2 opener (ClC-2), on HCO 3 -secretion in the rat stomach and duodenum, with a focus on the EP receptor subtypes involved in this action. Under urethane anesthesia, an ex-vivo chambered stomach or a duodenal loop was perfused with saline, and HCO 3 -secretion was measured at pH 7.0 using a pH stat-method. Lubiprostone (0.1-30 M) was perfused in the chamber or loop for 10 min. Indomethacin, ONO-8711 (an EP 1 antagonist), or AE5-599 (an EP 3 antagonist) was given s.c. 1 h before the lubiprostone treatment, while AE3-208 (an EP 4 antagonist) or CFTR inh -172 (a cystic fibrosis transmembrane conductance regulator (CFTR) inhibitor) was given i.p. 30 min before. Lubiprostone dosedependently and significantly increased HCO 3 -secretion in both the stomach ( 10 M) and duodenum ( 1 M). The stimulatory effect in the stomach was significantly abrogated by a pretreatment with the EP 1 antagonist, but not the EP 3 /EP 4 antagonists or CFTR inhibitor, while that in the duodenum was significantly attenuated by the EP 3 /EP 4 antagonists as well as the CFTR inhibitor. Indomethacin had no effect on the response of either tissue to lubiprostone. These results suggest that lubiprostone stimulated HCO 3secretion in the stomach and duodenum in a manner that was mediated by different EP receptor subtypes; the former was mediated by EP 1 receptors, while the latter was mediated by both EP 3 and EP 4 receptors. CFTR/ClC-2 may be involved in the response observed in the duodenum, but not in the stomach.
No takes yet. Share an insight, caveat, or question.
Takeuchi et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: